Evidence map›Paper›PMID 35273592›Full record

ArticleFrontiers in immunology2022

Cooperation Between Systemic and Mucosal Antibodies Induced by Virosomal Vaccines Targeting HIV-1 Env: Protection of Indian Rhesus Macaques Against Low-Dose Intravaginal SHIV Challenges.

Samir K Lakhashe, Mario Amacker, Dinesh Hariraju, Hemant K Vyas, Kyle S Morrison, Joshua A Weiner, Margaret E Ackerman, Vicky Roy, Galit Alter, Guido Ferrari and 7 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.5field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 7 institutions in 2 countries.

Samir K LakhasheTexas Biomedical Research Institute, San Antonio, TX, United States.
Mario AmackerDepartment of Pulmonary Medicine, Bern University Hospital, University of Bern, Bern, Switzerland.
Dinesh HarirajuTexas Biomedical Research Institute, San Antonio, TX, United States.
Hemant K VyasTexas Biomedical Research Institute, San Antonio, TX, United States.
Kyle S MorrisonDepartment of Microbiology and Immunology, Geisel School of Medicine at Dartmouth, Hanover, NH, United States.
Joshua A WeinerThayer School of Engineering, Dartmouth College, Hanover, NH, United States.
Margaret E AckermanDepartment of Microbiology and Immunology, Geisel School of Medicine at Dartmouth, Hanover, NH, United States.
Vicky RoyRagon Institute of Massachusetts General Hospital (MGH), Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, United States.
Galit AlterRagon Institute of Massachusetts General Hospital (MGH), Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, United States.
Guido FerrariDepartment of Surgery, Duke University, Durham, NC, United States.
David C MontefioriDepartment of Surgery, Duke University, Durham, NC, United States.
Georgia D TomarasDepartment of Surgery, Duke University, Durham, NC, United States.
Sheetal SawantDepartment of Surgery, Duke University, Durham, NC, United States.
Nicole L YatesDepartment of Surgery, Duke University, Durham, NC, United States.
Chris GastTexas Biomedical Research Institute, San Antonio, TX, United States.
Sylvain FleuryMymetics SA, Epalinges, Switzerland.
Ruth M RuprechtTexas Biomedical Research Institute, San Antonio, TX, United States.
Duke University · USDartmouth College · USTexas Biomedical Research Institute · USUniversity of Louisiana at Lafayette · USConcord Consortium · USRagon Institute of MGH, MIT and Harvard · USUniversity of Bern · CH

Funding

The Southwest National Primate Research Center Supplement- Infrastructure improvements of ABSL2 holding areasP51OD011133 · OD · TEXAS BIOMEDICAL RESEARCH INSTITUTE · PI Larry S. Schlesinger · 2012 to 2026
$129.7M
Social and Behavioral Sciences CoreP30AI064518 · NIAID · DUKE UNIVERSITY · PI Nwora Lance Okeke · 2005 to 2026
$50.5M
Vaccine immunogenicity and efficacy in the rhesus macaque/SHIV modelU19AI142636 · NIAID · UNIVERSITY OF LOUISIANA AT LAFAYETTE · PI FLEURY, SYLVAIN, VILLINGER, FRANCOIS J · 2019 to 2023
$8.8M
NIAID NIH HHS P30 AI064518NIAID NIH HHS U19 AI142636NIH HHS P51 OD011133
6 · The paper itself

Abstract

A virosomal vaccine inducing systemic/mucosal anti-HIV-1 gp41 IgG/IgA had previously protected Chinese-origin rhesus macaques (RMs) against vaginal SHIV

Indexed as

AIDS VaccinesHIV-1HIV SeropositivitySimian Immunodeficiency VirusAnimalsFemaleHumansImmunoglobulin AImmunoglobulin GMacaca mulattaVirosomesAIDS VaccinesImmunoglobulin AImmunoglobulin GVirosomesHIV-1 gp41Indian-origin rhesus macaque modelintramuscular prime/intranasal boost vaccinationintravaginal challengemucosal immunitySHIVvirosomal vaccinevirosomes

Identifiers

PMID35273592
PMCPMC8902080
OpenAlexW4212808179

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.